Mitsubishi Tanabe Pharma achieves 100 billion Yen profit in FY 2012, blockbuster is Remicade, a treatment for rheumatoid arthritis

Mitsubishi Tanabe Pharma News Release, May 9, 2013

Mitsubishi Tanabe Pharma achieves 100 billion Yen profit in FY 2012, blockbuster is Remicade, a treatment for rheumatoid arthritis
Scroll to top